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Abstract: Tocotrienols have been reported to improve lipid profiles, reduce atherosclerotic 
lesions, decrease blood glucose and glycated haemoglobin concentrations, normalise blood 
pressure in vivo and inhibit adipogenesis in vitro, yet their role in the metabolic syndrome 
has not been investigated. In this study, we investigated the effects of palm tocotrienol-rich 
fraction (TRF) on high carbohydrate, high fat diet-induced metabolic, cardiovascular and 
liver dysfunction in rats. Rats fed a high carbohydrate, high fat diet for 16 weeks developed 
abdominal obesity, hypertension, impaired glucose and insulin tolerance with increased 
ventricular stiffness, lower systolic function and reduced liver function. TRF treatment 
improved ventricular function, attenuated cardiac stiffness and hypertension, and improved 
glucose and insulin tolerance, with reduced left ventricular collagen deposition and 
inflammatory cell infiltration. TRF improved liver structure and function with reduced 
plasma liver enzymes, inflammatory cell infiltration, fat vacuoles and balloon hepatocytes. 
TRF reduced plasma free fatty acid and triglyceride concentrations but only omental fat 
deposition was decreased in the abdomen. These results suggest that tocotrienols protect 
the heart and liver, and improve plasma glucose and lipid profiles with minimal changes in 
abdominal obesity in this model of human metabolic syndrome. 
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1. Introduction 
Dietary changes have been perceived as the first-line intervention in metabolic syndrome, targeting 
insulin sensitivity and preventing or correcting the associated metabolic and cardiovascular 
abnormalities. Targeting illness with selected components of foods, defined as treatment with 
functional foods or nutrapharmacology, could provide protection against cardiovascular diseases and 
diabetes [1,2]. Functional or medicinal foods and phytonutrients are widely accepted for maintaining 
well-being, enhancing health, and modulating immune function to prevent specific diseases [3].  
Vitamin E is a group of closely-related phytochemicals including the tocopherols and tocotrienols, 
with potential cardiovascular and metabolic health-promoting properties [4]. They share a common 
chromanol ring with the tocopherols having a saturated phytyl side chain, differing from the farnesyl 
side chain with three double bonds in the tocotrienols. Each group has α-, β-, γ- and δ-homologues [5]. 
While in vitro and in vivo studies on tocopherols demonstrated positive antioxidant and  
anti-atherogenic effects, the clinical evidence was inconclusive or even negative [6]. This lack of 
therapeutic value of the tocopherols makes it worthwhile to investigate the efficacy of the tocotrienols, 
as these homologues may have unique functions [7,8]. Tocotrienols have been claimed to possess 
neuroprotective, anticancer and cholesterol-lowering properties that are often not exhibited by 
tocopherols [7]. Neurodegeneration in mouse hippocampal HT4 neural cells was prevented with  
250 nanomolar concentrations of α-tocotrienol, but not α-tocopherol [9]. This suggests that the 
molecular and therapeutic targets of the tocotrienols are distinct from those of the tocopherols [7]. In 
addition to their shared antioxidant activities, tocotrienols have anti-inflammatory [10] and  
anti-angiogenic activities unlike the tocopherols [11,12]. These observations are of particular note 
considering the low plasma tocotrienol concentrations achieved in such studies, suggesting powerful 
metabolic effects. These activities could play vital roles in attenuating metabolic syndrome. There is 
little data on the ability of tocotrienols to reverse chronic diet-induced changes in humans. Hence, this 
study has measured the changes following intervention with palm tocotrienol-rich fractions (TRF) in a 
rat model of chronic diet-induced cardiovascular, metabolic and liver changes [13,14]. Palm-derived 
TRF is as tocopherol-tocotrienol mixture, at a ratio of approximately 1:3. The mixture is a commercial 
product for human consumption from companies including Golden Hope Bioganic (Sime Darby), 
Carotech, Palm Nutraceuticals, Eisai and Davos Life Sciences. However, individual homologues have 
been difficult to obtain in sufficient quantities for chronic animal studies.  
2. Experimental Section  
2.1. Rats and Diets 
The experimental groups consisting of male Wistar rats (aged 9–10 weeks; weighing 329 ± 2 g,  
n = 32) were obtained from The University of Queensland Biological Resources unit and individually 
housed at the University of Southern Queensland’s Animal House Facility. All experimental protocols 
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were approved by the Animal Experimentation Ethics Committee of the University of Southern 
Queensland, under the guidelines of the National Health and Medical Research Council of Australia. 
Rats were divided into 4 groups: (i) corn starch (C, n = 8), (ii) high carbohydrate, high fat (H, n = 8),  
(iii) C + tocotrienol-rich fraction (TRF) (CT, n = 8), (iv) H + TRF (HT, n = 8). This TRF contained  
α-tocotrienol (31.9%), β-tocotrienol (2.1%), γ-tocotrienol (24.8%) and δ-tocotrienol (18.3%) together 
with α-tocopherol (22.9%). 120 mg/kg/day palm TRF dissolved in vitamin E-stripped palm olein  
(240 mg TRF/mL palm olein, Malaysian Palm Oil Board, Malaysia) was given for the final 8 weeks of 
the 16 weeks protocol via once-daily oral gavage. This dose was chosen as the reported oral  
no-observed-adverse-effects level in male rats given a similar tocotrienol-tocopherol mixture [15]. All 
experimental groups were housed in a temperature-controlled, 12-h light/dark cycle environment with 
ad libitum access to water and food. Measurements of body weight and food and water intakes were 
taken daily to monitor the day-to-day health of the rats. Feed conversion efficiency (%) was calculated as:  
feed conversion efficiency (%) =
increase in body weight (%)
daily energy intake (kJ)
 ´100  
All group-specific diets were prepared in our laboratory. Corn starch diet was prepared by thorough 
mixing of corn starch, powdered rat feed (meat-free rat and mouse feed; Speciality Feeds, Glen 
Forrest, WA, Australia), Hubble, Mendel and Wakeman salt mixture (MP Biochemicals, Seven Hills, 
NSW, Australia) and water, while the corn starch and part of water were replaced with condensed 
milk, fructose and beef tallow in the high carbohydrate, high fat diet [14]. The drinking water in all 
high carbohydrate, high fat-fed rats was augmented with 25% fructose. 
2.2. Echocardiography 
Echocardiography was performed by trained cardiac sonographers at the Medical Engineering 
Research Facility, The Prince Charles Hospital, Brisbane, Australia. Rats were anaesthetised via 
intraperitoneal injection with Zoletil (tiletamine 15 mg/kg, zolazepam 15 mg/kg) and Ilium Xylazil 
(xylazine 10 mg/kg). Echocardiographic images were obtained using the Hewlett Packard Sonos 5500 
(12 MHz frequency fetal transducer) at an image depth of 3 cm using two focal zones. Measurements 
of left ventricular posterior wall thickness and internal diameter were made using two-dimensional  
M-mode taken at mid-papillary level [13,16]. 
2.3. Body Composition Measurements 
Dual-energy X-ray absorptiometric (DXA) measurements using a Norland XR36 DXA instrument 
(Norland Corp., Fort Atkinson, WI, USA) were performed on the rats after 16 weeks of feeding, 2 days 
before rats were killed for pathophysiological assessments. DXA scans were analysed using the 
manufacturer’s recommended software for use in laboratory animals (Small Subject Analysis Software, 
version 2.5.3/1.3.1; Norland Corp.) as previously described [17]. The precision error of lean mass for 
replicate measurements, with repositioning, was 3.2%. Visceral adiposity index (%) was calculated 
from wet weights of fat pads at euthanasia as:  
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visceral adiposity index (%) = 
retroperitoneal fat (g)+omental fat (g)+epididymal fat (g)
body weight (g)
´100  
and expressed as adiposity per cent [18]. 
2.4. Assessment of Physiological Parameters  
Systolic blood pressure was measured after 0, 4, 8, 12 and 16 weeks under light sedation with i.p. 
injection of Zoletil (tiletamine 15 mg/kg, zolazepam 15 mg/kg), using an MLT1010 Piezo-Electric 
Pulse Transducer (ADInstruments) and inflatable tail-cuff connected to a MLT844 Physiological 
Pressure Transducer (ADInstruments) and PowerLab data acquisition unit (ADInstruments, Sydney, 
Australia). Abdominal circumference was measured using a standard measuring tape under light 
sedation. Rats were killed with an intraperitoneal injection of pentobarbitone sodium (100 mg/kg).  
2.5. Oral Glucose Tolerance Test and Insulin Tolerance Test 
Oral glucose tolerance tests were performed after 0, 8 and 16 weeks of diet. After 12 h of fasting, 
blood glucose concentrations were measured in blood samples taken from the tail vein. Subsequently, 
each rat was treated with glucose (2 g/kg) via oral gavage. Tail vein blood samples were taken every 
30 min up to 120 min following glucose administration. The blood glucose concentrations were 
analysed with a Medisense Precision Q.I.D glucose meter (Abbott Laboratories, Bedford, MA, USA).  
For insulin tolerance testing, basal blood glucose concentrations were measured after 4–5 h of food 
deprivation as above. The rats were injected i.p. with 0.33 IU/kg insulin-R (Eli Lilly Australia, West 
Ryde, NSW, Australia), and tail vein blood samples were taken at 0, 30, 60, 90 and 120 min. Rats were 
withdrawn from the test if the blood glucose concentrations dropped below 1.1 mmol/L, and 4 g/kg 
glucose was administered immediately by oral gavage to reverse hypoglycaemia. 
2.6. Organ Bath Studies 
Changes in the responsiveness of thoracic aorta were defined using organ bath studies. Thoracic 
aortic rings (4 mm in length) were suspended in an organ bath chamber with a resting tension of  
10 mN. Cumulative concentration-response (contraction) curves were measured for noradrenaline 
(Sigma-Aldrich Australia); concentration-response (relaxation) curves were measured for acetylcholine 
(Sigma-Aldrich Australia) or sodium nitroprusside (Sigma-Aldrich Australia) in the presence of a 
submaximal contraction to noradrenaline [14]. 
2.7. Isolated Heart Preparation  
The left ventricular function of the rats in all treatment groups was assessed using the Langendorff 
heart preparation. Terminal anaesthesia was induced via i.p. injection of pentobarbitone sodium  
(100 mg/kg). Once anaesthesia was achieved, heparin (1000 IU) was injected into the right femoral 
vein. After removal of the heart, isovolumetric ventricular function was measured by inserting a latex 
balloon into the left ventricle connected to a Capto SP844 MLT844 physiological pressure transducer 
and Chart software on a Maclab system. All left ventricular end-diastolic pressure values were 
measured by pacing the heart at 250 beats per minute using an electrical stimulator. End-diastolic 
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pressure was obtained starting from 0 mmHg up to 30 mmHg. The right and left ventricles were 
separated and weighed. Diastolic stiffness constant (κ, dimensionless) was calculated [16].  
2.8. Organ Weights 
Following euthanasia, the heart, liver, kidneys, visceral fat pads and spleen were removed and 
blotted dry for weighing. All organ weights were normalised relative to tibial length at the time of 
removal and presented in mg/mm. 
2.9. Histology of Heart and Liver 
Immediately after removal, heart and liver tissues were fixed in 10% buffered formalin with change 
of formalin every 3 days for 10 days to remove traces of blood from the tissue. The samples were then 
dehydrated and embedded in paraffin wax. Thin sections (5 μm) of left ventricle and the liver were cut 
and stained with haematoxylin and eosin stain for determination of inflammatory cell infiltration. 
Collagen distribution was observed in the left ventricle following picrosirius red staining. Laser 
confocal microscopy (Zeiss LSM 510 upright Confocal Microscope) was used to determine the extent 
of collagen deposition in selected regions. 
2.10. Plasma Analyses 
Blood was collected from the abdominal aorta following euthanasia and centrifuged at 5000× g for 
15 min within 30 min of collection into heparinised tubes. Plasma was separated and transferred to 
Eppendorf tubes for storage at −20 °C before analysis. Plasma concentrations of total cholesterol, 
triglycerides, non-esterified fatty acids (NEFA), activities of plasma alanine transaminase (ALT) and 
aspartate transaminase (AST) were determined using kits and controls supplied by Olympus using an 
Olympus analyser (AU 400 Tokyo, Japan) [14]. 
2.11. Statistical Analysis  
All data sets were represented as mean ± standard error of mean (SEM). Comparisons of findings 
between groups were made via statistical analysis of data sets using one-way and two-way analysis of 
variance (ANOVA). When interaction and/or the main effects were significant, means were compared 
using Newman-Keuls multiple-comparison post hoc test. A p-value of <0.05 was considered as 
statistically significant. All statistical analyses were performed using Graph Pad Prism version 5.00  
for Windows. 
3. Results  
3.1. Cardiovascular Structure and Function  
Feeding of the high carbohydrate, high fat (H) diet for 16 weeks increased systolic blood pressure 
compared with cornstarch (C) diet. With TRF supplementation for 8 weeks, blood pressure was 
normalised in rats fed with H diet (Figure 1). H feeding diminished noradrenaline contraction in isolated 
thoracic aortic rings (Figure 2A) and vascular relaxation responses to sodium nitroprusside (SNP) and 
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acetylcholine (ACh) compared with C rats (Figure 2B,C). With TRF, thoracic aortic contractions to 
noradrenaline were improved (Figure 2A) but relaxation responses were unchanged (Figure 2B,C).  
Figure 1. Tail-cuff measurement of systolic blood pressure recorded at 0, 4, 8, 12 and  
16 weeks for C, CT, H and HT diet-fed rats. Data shown as means ± SEM. Endpoint means 
with different letters in each data set are significantly different. n = 8/group. 
 
Figure 2. Cumulative concentration-response curves for noradrenaline (A), sodium 
nitroprusside (B) and acetylcholine (C) in thoracic aortic rings from C, CT, H and HT-diet 
fed rats. Data shown as means ± SEM. Endpoint means with different letters in each data 
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Compared to C group, H rats demonstrated eccentric hypertrophy, defined as an increased left 
ventricular weight and internal diameter in diastole (LVIDd) without any changes in relative wall 
thickness, with increased stroke volume and cardiac output (Table 1). H rats showed impaired systolic 
function seen as reduced fractional shortening. H rats showed decreased contractility, measured as 
maximal rate of positive rise of pressure (+dP/dt) and negative rise of pressure (−dP/dt), and LV 
developed pressure, in the isolated heart. Compared with H rats, relative wall thickness of HT rats was 
reduced. Systolic function was improved in TRF-treated rats, as shown by the increased fractional 
shortening, ejection fraction and cardiac output and decreased ejection time. Functionally, the increased 
diastolic stiffness in H rats was decreased in HT rats with improved −dP/dt. Histology of the H heart 
showed marked inflammatory cells infiltration (Figure 3C) and collagen deposition (Figure 3G) in the 
left ventricle compared with C rats. These changes were normalised with TRF treatment (Figure 3D,H). 
Table 1. Changes in cardiovascular structure and function in C, CT, H and HT diet-fed groups. 
Variables C CT H HT 
 p  
Diet Treatment Interaction 
LVIDd, mm 6.40 ± 0.21 
a 
7.42 ± 0.22 
b 
7.64 ± 0.26 
b 
8.02 ± 0.10 
b 
0.0001 0.0020 0.1280 
LVPWd, mm 1.78 ± 0.03 1.86 ± 0.07 1.83 ± 0.03 1.85 ± 0.06 0.7014 0.2958 0.5658 
Relative wall thickness 0.50 ± 0.02 
a,b 
0.47 ± 0.04 
a,b 
0.54 ± 0.02 
a 
0.45 ± 0.01 
b 
0.7876 0.0123 0.2189 
Fractional shortening, % 48.0 ± 1.1 
a 
51.5 ± 1.5 
a 
42.5 ± 0.6 
b 
48.6 ± 1.8 
a 
0.0038 0.0011 0.3175 
Ejection fraction, % 83.3 ± 0.8 
b,c 
88.3 ± 1.1 
a 
81.0 ± 0.6 
c 
86.1 ± 1.5 
a,b 
0.0414 <0.0001 0.9736 
Heart rate, bpm 268 ± 22 288 ± 25 264 ± 24 308 ± 18 0.7448 0.1659 0.6057 
Stroke volume, mL 0.28 ± 0.01 
b 
0.38 ± 0.03 
a 
0.42 ± 0.04 
a 
0.46 ± 0.01 
a 
0.0005 0.0096 0.3497 
Cardiac output, mL/min 74.2 ± 3.9 
a,b
 98.1 ± 7.3 
a,b 
108.9 ± 12.25 
b 
143.1 ± 9.1 
c 
<0.0001 0.0045 0.091 
LV developed pressure, 
mmHg 
64.7 ± 8.8 
a 
43.8 ± 4.5 
b 
32.7 ± 2.3 
b 
33.0 ± 2.6 
b 
0.0003 0.0601 0.0540 
(+)dP/dt, mmHg/s 1079 ± 104 
a 
844 ± 89 
a,b 
599 ± 39 
b 
766 ± 97 
a,b 
0.0031 0.6956 0.0266 
(−)dP/dt, mmHg/s 614 ± 66 a 507 ± 49 a,b 359 ± 39 b 512 ± 89 a,b 0.0606 0.7235 0.0520 
Diastolic stiffness, κ 22.8 ± 0.7 c 23.5 ± 0.3 c 28.8 ± 0.5 a 26.4 ± 0.3 b <0.0001 0.1003 0.0037 
Ascending aortic flow, 
m/s 
0.90 ± 0.02 0.91 ± 0.07 0.95 ± 0.04 1.05 ± 0.07 0.1064 0.3305 0.4432 
Descending aortic flow, 
m/s 
0.87 ± 0.04 0.92 ± 0.09 0.93 ± 0.03 0.88 ± 0.07 0.8777 0.9607 0.4405 
Ejection time, s 84.5 ± 3.2 
a 
89.6 ± 3.0 
a 
98.1 ± 2.5 
b 
88.3 ± 2.2 
a 
0.0349 0.3974 0.0112 
Estimated LV mass, 
Litwin, g 
0.89 ± 0.03 0.89 ± 0.07 0.98 ± 0.05 1.01 ± 0.03 0.0310 0.7471 0.7316 
LV + septum wet weight, 
mg/mm 
19.5 ± 0.7 17.8 ± 0.8 20.7 ± 0.9 20.3 ± 1.1 0.0427 0.2536 0.5082 
Right ventricle wet 
weight, mg/mm 
4.8 ± 0.7 
a,b 
3.5 ± 0.4 
b 
5.4 ± 0.5 
a 
4.0 ± 0.4 
a,b 
0.2726 0.0099 0.9280 




21.3 ± 0.8 25.3 ± 1.9 24.3 ± 1.1 0.2402 0.0789 0.4212 
Systolic wall stress, 
mmHg 
81.9 ± 1.8 80.6 ± 5.0 101.1 ± 8.1 96.1 ± 6.6 0.0060 0.5944 0.7547 
Each value is mean ± SEM. Groups with letters different from others are significantly different (p < 0.05, n = 8). 
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Figure 3. Haematoxylin and eosin staining of left ventricle (20×) showing inflammatory 
cells (marked as “ic”) as dark spots outside the myocytes in C (A), CT (B), H (C) and HT (D) 
diet-fed rats. Picrosirius red staining of left ventricular interstitial collagen deposition (40×) 
in C (E), CT (F), H (G) and HT (H) diet-fed rats; collagen deposition is marked as “cd”. 
 
3.2. Dietary Intake, Body Parameters and Lipid Profile 
After 16 weeks, rats fed the H diet had increased body weight compared with C. H-fed rats had 
increased abdominal circumference and their visceral adiposity index was significantly higher than that 
of C rats (6.8% ± 0.6% compared to 3.6% ± 0.2%, respectively, Table 2). Consistent with the body 
weight results, fat mass and total visceral adipose tissue (retroperitoneal, epididymal and omental fat 
pads) in H rats were higher than in C rats. TRF treatment in H rats reduced omental, but not 
epididymal or perirenal fat pads, reduced abdominal circumference and increased food intake and lean 
mass. H rats had higher total cholesterol, triglyceride and NEFA plasma concentrations compared with  
C rats; TRF reduced triglyceride and NEFA but not total cholesterol concentrations (Table 2). 
Table 2. Dietary intakes, body composition, metabolic indices and organ wet weights in C, 
CT, H and HT diet-fed rats. 
Variables C CT H HT 
 p  
Diet Treatment Interaction 
Food intake, g/day 38.2 ± 1.0 a 34.2 ± 0.8 b 22.0 ± 0.9 c 25.6 ± 0.5 d <0.0001 0.7595 0.0001 
Water intake, mL/day 32.4 ± 2.8 a 26.2 ± 1.0 b 23.3 ± 1.2 b 26.1 ± 1.4 b 0.0132 0.3377 0.0148 
Body weight gain, % 11.0 ± 1.0 a,b 8.6 ± 0.9 b 15.0 ± 1.5 a 14.4 ± 1.4 a 0.0005 0.2425 0.4535 
Energy intake, kJ/day 443.2 ± 5.6 a 397.5 ± 11.6 b 480.1 ± 13.5 c 556.3 ± 14.7 d <0.0001 0.2093 <0.0001 
Feed conversion efficiency, % 2.4 ± 0.2 2.2 ± 0.3 3.0 ± 0.3 2.8 ± 0.2 0.0364 0.4079 0.9615 
Bone mineral content, g 12.8 ± 0.1 13.0 ± 1.3 15.0 ± 0.6 14.9 ± 0.3 0.0092 0.9109 0.8408 
Total fat mass, g 90.6 ± 7.0 b 83.2 ± 6.2 b 193.7 ± 20.1 a 181.2 ± 9.8 a <0.0001 0.4197 0.8362 
Total lean mass, g 335.9 ± 9.2 a 288.8 ± 8.1 b 257.7 ± 8.7 c 270.1 ± 11.1 b <0.0001 0.0738 0.0036 
Abdominal circumference, cm 19.8 ± 0.1 c 19.7 ± 0.1c 22.4 ± 0.3 a 21.8 ± 0.2 b <0.0001 0.0742 0.2337 
Visceral adiposity index, % 3.6 ± 0.2 a 4.3 ± 0.4 a 6.8 ± 0.6 b 6.6 ± 0.3 b <0.0001 0.6177 0.2546 
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Table 2. Cont. 
Tissue wet weight, mg/mm tibial length 
Retroperitoneal fat 136.9 ± 11.6 a 148.7 ± 11.0 a 350.9 ± 29.3 b 316.7 ± 21.9 b <0.0001 0.5777 0.2583 
Epididymal fat 108.7 ± 8.8 a 119.5 ± 12.9 a 204.3 ± 23.3 b 206.8 ± 16.7 b <0.0001 0.6883 0.8005 
Omental fat 63.0 ± 6.7 c 77.9 ± 9.2 c 160.1 ±16.8 a 127.8 ± 6.9 b <0.0001 0.4207 0.0365 
Total abdominal fat 302.5 ± 23.5 a 346.0 ± 29.1 a 690.6 ± 71.2 b 651.2 ± 35.9 b <0.0001 0.0018 0.0161 
Plasma lipid profile 
Total cholesterol, mmol/L  1.23 ± 0.07 a 1.63 ± 0.07 b 1.74 ± 0.09 b 1.60 ± 0.09 b 0.0062 0.1252 0.0026 
Triglyceride, mmol/L 0.34 ± 0.04 a 0.44 ± 0.05 a 0.90 ± 0.17 b 0.60 ± 0.09 b 0.0082 0.6539 0.2530 
NEFA, mmol/L 0.98 ± 0.14 a 1.46 ± 0.11a 2.28 ± 0.25 b 1.74 ± 0.16 a 0.0050 0.0394 0.0183 
Liver enzymes 
ALT, U/L 24.8 ± 2.8 a 28.7 ± 2.2 a 43.9 ± 6.5 b 25.8 ± 2.0 a 0.0473 0.0779 0.0087 
AST, U/L 67.1 ± 6.8 a 65.7 ± 3.9 a 96.6 ± 3.8 b 58.0 ± 2.3 a 0.0233 0.0002 0.0004 
Liver wet weight, mg/mm 234.9 ± 10.6 a 240.4 ± 8.8 a 330.2 ± 13.8 b 324.6 ± 4.6 b <0.0001 0.9966 0.5774 
Fasting plasma glucose, mmol/L 
0 week 3.5 ± 0.1 3.6 ± 0.1 3.7 ± 0.1 3.5 ± 0.1 0.0016 0.3305 0.0585 
8 weeks 3.8 ± 0.2 a 3.6 ± 0.2 a 5.0 ± 0.1 b 5.0 ± 01 b <0.0001 0.5322 0.5322 
16 weeks 3.1 ± 0.2 c 3.0 ± 0.1 c 4.6 ± 0.2 a 3.6 ± 0.2 b <0.0001 0.0050 0.0187 
Each value is mean ± SEM. Groups with letters different from others are significantly different (p < 0.05, n = 8). 
3.3. Glucose Handling 
H rats had higher fasting blood glucose concentration than C rats (Table 2) TRF treatment 
decreased the blood glucose concentrations in HT rats. The plasma glucose response to oral glucose 
loading was greater in H rats than C rats (Figure 4A). At 120 min, HT, CT and C rats had lower 
plasma glucose concentrations than H rats. In the insulin tolerance test, C, CT and HT rats had lower 
area under the curve than H rats (Figure 4B). 
Figure 4. Oral glucose (2 g/kg) (A) and insulin (0.33 IU/kg) (B) tolerance in C, CT, H and 
HT-diet fed groups. Data shown as means ± SEM. Endpoint means with different letters in 
each data set significantly differ. n = 8/group. 
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3.4. Hepatic Structure and Function 
H rats had 1.8-fold greater plasma ALT and AST activities compared with C rats (Table 2). Liver 
weights of H rats were higher than C rats. With TRF, plasma AST and ALT activities were reduced by 
41.2% and 40%, respectively, in HT rats. There were no differences in liver weight of HT and H rats. 
H rats developed fat vacuoles within the hepatocytes, showing ballooned hepatocytes with portal 
inflammatory cell infiltration compared with C rats (Figure 5E,G). Livers from the HT group showed a 
markedly attenuated degree of fatty change, with decreased fat vacuole size and number compared 
with the H group (Figure 5H). In addition, the HT rats displayed normalised portal inflammatory cells 
infiltration compared with H group (Figure 5C,D). 
Figure 5. Haematoxylin and eosin staining of hepatocytes showing inflammatory cells 
around the portal region (marked as “ic”) (20×) in C (A), CT (B), H (C), and HT (D)  
diet-fed rats and hepatocytes with enlarged fat vacuole (marked as “fv”) (40×) and 
ballooned hepatocyte (marked as “bc”) in C (E), CT (F), H (G) and HT (H) diet-fed rats. 
 
4. Discussion 
This study shows improved metabolic parameters, and cardiovascular and liver structure and 
function, with smaller changes in abdominal obesity, in rats on a high carbohydrate, high fat diet 
administered TRF, a mixture of α-tocopherol, α-tocotrienol, γ-tocotrienol and δ-tocotrienol. We have 
shown that this high carbohydrate, high fat diet induces pathophysiological changes that resemble 
human metabolic syndrome [13], a syndrome that includes abdominal obesity, hyperglycaemia, 
dyslipidaemia, hypertension and fatty liver. Further, the changes in these rats can be reversed by 
interventions with compounds derived from foods, such as purple carrot extract high in  
anthocyanins [14], rutin from onions [19] and quercetin from apples [20]. Tocotrienols as important 
nutrients in food have been reported to change the individual parameters in the metabolic syndrome, 
including improved lipid profiles, decreased blood glucose concentrations and lowered blood  
pressures [4]. Oral supplementation of α-tocotrienol increased concentrations in many organs with 
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skin, adipose tissue, liver, brain, ovaries and the heart as preferred destinations [21,22]. Treatment of 
the metabolic syndrome with tocotrienols could then improve the different aspects of metabolic 
syndrome including obesity, insulin resistance and cardiovascular disease, as an alternative to treating 
each risk factor with a separate intervention with the increased risks of polypharmacy [23]. TRF is 
Generally Recognised as Safe (GRAS) with no indication of significant adverse effects related to 
tocotrienol consumption at the dose used in this study; further, TRF products are commercially 
available with trade names including Tocomin, Gold TriE and Carotino TRF [24]. 
Several mechanisms have been proposed for the tocotrienol-induced improvements shown in this 
study. The reduced blood pressure with tocotrienols in Spontaneously Hypertensive Rats may result 
from increased total antioxidant status and superoxide dismutase activity with reduced lipid 
peroxidation [25] and increased production of prostacyclin [26]. Possible mechanisms for the 
decreased ventricular fibrosis include scavenging oxygen species to alleviate inflammation, and  
down-regulation of TGF-β1 which induces fibrosis [27]. Increases in collagen deposition are linked to 
the excess production of advanced glycation end-products (AGE) [28] that increase collagen  
cross-linking and deposition, increasing myocardial stiffness. TRF decreased AGE in STZ-induced 
diabetic rats [29]. Tocotrienols improved metabolic parameters including glucose utilisation and 
insulin sensitivity [29–31]. This may lead to decreased plasma triglycerides and non-esterified fatty 
acids since insulin is a potent suppressor of circulating NEFA concentrations through suppression of 
hormone-sensitive lipase, up-regulation of lipoprotein lipase [32] and maintaining a constant rate of 
free fatty acid re-esterification apart from enhancing glucose uptake and glycolysis, switching energy 
production from dominant fat oxidation to prevalent carbohydrate utilisation [33]. Tocotrienols reduce 
cancer growth by inhibiting angiogenesis [11,12]; δ-tocotrienol induced apoptosis in endothelial cells 
through growth factor-dependent phosphatidylinositol-3 kinase/PDK/Akt signalling [12]. Similar 
responses in adipose tissue should decrease growth of fat pads [4]. Further, our results indicate 
improved liver structure and function following TRF treatment. 
A key change that may improve cellular survival is the reduced infiltration of inflammatory cells in 
the heart and liver, as shown in this study. Inflammation may initiate both insulin resistance and 
vascular dysfunction [34]. TRF inhibited the release of inflammatory mediators such as interleukin-6 
and nitric oxide from macrophages in vitro [10]. While we have not measured changes in 
proinflammatory cytokines or other plasma biomarkers in this study, previous studies suggest that TRF 
inhibits production and release of TNF-α, TGF-β1 and IL-1β in STZ-induced diabetic rats [35]. The 
histology suggests that the anti-inflammatory responses are important and future studies on TRF and 
the individual homologues should include measurement of relevant biomarkers in plasma and their 
expression in tissues [36]. Damaged cells may show an increase in phosphorylated c-Src associated 
with pro-death signalling in myocytes [37] while increased Akt phosphorylation is generally associated 
with cardiomyocyte survival [38,39]. In neurones, α-tocotrienol blocked glutamate-induced death by 
suppressing glutamate-induced early activation of c-Src kinase [40], so tocotrienols may enhance 
cardiomyocte survival by preventing c-Src activation and enhancing Akt phosphorylation.  
TRF did not reduce visceral adiposity in this study, unlike other dietary interventions in this rat 
model [14,19,20,41]. In contrast, supplementation of rice bran tocotrienol mixture or α-tocopherol 
reduced body weight of F344 rats fed a high fat diet [42]. An in vitro study on 3T3-L1 cells suggested 
that α- and γ-tocotrienols reduced body fat by suppressing adipocyte differentiation and Akt 
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phosphorylation [43]. Interpretation of the results is complicated by possible interactions between 
tocopherols and tocotrienols in TRF; as an example, tocopherol attenuated the cholesterol-lowering 
effect of γ-tocotrienol [44]. Tocopherols may decrease the responses to tocotrienols as the body prefers 
to absorb α-tocopherol rather than tocotrienols [5]. Further, preferential absorption has been reported 
for α-tocotrienol over γ-tocotrienol, δ-tocotrienol and α-tocopherol in thoracic duct-cannulated  
rats [45]. Differences in the number of methyl groups on the chromanol rings of the tocotrienols could 
affect the lipophilicity of the molecule and transportation to the lymphatic system via biological 
membranes [46]. In addition, interference by α-tocopherol has been recently reviewed [47].  
α-Tocopherol may inhibit the uptake of α- and γ-tocotrienols to peripheral tissues such as heart, skin, 
aorta and perirenal adipose tissue, attributed to transport of tocotrienols and tocopherols to tissues by 
liver-dependent transport mechanisms [48]. 
5. Conclusions  
TRF attenuated the structural and functional changes in the heart and liver associated with 
metabolic syndrome, and improved glucose metabolism and lipid profile. Prevention of inflammation 
may be the key mechanism. Although TRF showed minimal effects on obesity, studies with individual 
tocotrienols are warranted since the pure compounds may produce different responses to the mixture. 
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